Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Cytek Biosciences, Inc. (CTKB)
Company Research
Source: Yahoo! Finance
Profit margin: 1.8% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. EPS: US$0.007 (up from US$0.047 loss in 3Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates. Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Performance of the American Life Sciences industry. The company's shares are up 51% from a week ago. Before we wrap up, we've discovered 1 warning sign for Cytek Biosciences that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst
Show less
Read more
Impact Snapshot
Event Time:
CTKB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTKB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTKB alerts
High impacting Cytek Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CTKB
News
- Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramGlobeNewswire
- Cytek Biosciences, Inc. (NASDAQ: CTKB) had its price target raised by analysts at Piper Sandler from $8.00 to $8.50. They now have an "overweight" rating on the stock.MarketBeat
- Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterGlobeNewswire
- Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ... [Yahoo! Finance]Yahoo! Finance
CTKB
Earnings
- 11/5/24 - Beat
CTKB
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- CTKB's page on the SEC website